Companies: 10,795·Total market cap: $144.5T
DBV Technologies S.A.

DBV Technologies S.A.

DBVTNASDAQHealthcare● Active
$16.59
$-0.99(-5.63%)
Market Cap$396861650
P/E Ratio
52W High$26.185
52W Low$8.3

DBV Technologies S.A. (DBVT) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

dbvt · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for DBV Technologies S.A. (DBVT) measures how much investors pay for each dollar of the company's trailing earnings. DBVT's current PE ratio of N/A is calculated by dividing its stock price of $16.59 by its TTM earnings per share of -$0.39.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-0.41
Based on 2 analysts
EPS (TTM)
-$0.39
TTM · diluted EPS
PEG Ratio
-0.49
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · DBV Technologies S.A. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2008 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
DBV Technologies S.A.
DBV Technologies S.A.You
DBVT
$397MN/A-$0.39
Altimmune, Inc.
Altimmune, Inc.
ALT
$239MN/A-$1.00
Amarin Corporation plc
Amarin Corporation plc
AMRN
$288MN/A-$1.87
Annexon, Inc.
Annexon, Inc.
ANNX
$633MN/A-$1.33
Alto Neuroscience, Inc.
Alto Neuroscience, Inc.
ANRO
$641MN/A-$2.19
Cellectis S.A.
Cellectis S.A.
CLLS
$307MN/A-$0.67
enGene Holdings Inc.
enGene Holdings Inc.
ENGN
$84MN/A-$2.29

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 10 of 18 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-1.70
2024-12-31
FY2024
$-1.18
2023-12-31
FY2023
$-0.76
2022-12-31
FY2022
$-1.24
2021-12-31
FY2021
$-1.78
2020-12-31
FY2020
$-2.95
2019-12-31
FY2019
$-3.22
2018-12-31
FY2018
$-3.47
2017-12-31
FY2017
$-7.16
2016-12-31
FY2016
$-5.17

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for DBV Technologies S.A. (DBVT) measures how much investors pay for each dollar of the company's trailing earnings. DBVT's current PE ratio of N/A is calculated by dividing its stock price of $16.59 by its TTM earnings per share of -$0.39.

PE Ratio = Stock Price ÷ EPS (TTM)
= $16.59 ÷ -$0.39 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

DBVT pe ratio · 6 questions

DBVT's current PE ratio is N/A as of 2026-06-08, based on a stock price of $16.59 and TTM EPS of -$0.39. Data sourced from Financial Modeling Prep via DBVT's SEC 10-K and 10-Q filings.

DBVT PE ratioWhat is DBVT PE ratioCurrent PE ratio of DBVTDBVT PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · DBV Technologies S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08